Theoretical study on the interactions between ibrutinib and gold nanoparticles for being used as drug delivery in the chronic lymphocytic leukemia

被引:5
|
作者
Sanchez-Coronilla, Antonio [1 ]
Martin, Elisa, I [2 ]
Jose Fernandez-de-Cordova, Francisco [3 ]
Prado-Gotor, Rafael [4 ]
Hidalgo, Jose [1 ]
机构
[1] Univ Seville, Fac Farm, Dept Quim Fis, E-41012 Seville, Spain
[2] Univ Seville, Fac Quim, Dept Ingn Quim, E-41012 Seville, Spain
[3] CSIC Univ Sevilla, Inst Invest Quim IIQ, Ave Amer Vespucio 49, E-41092 Seville, Spain
[4] Univ Seville, Fac Quim, Dept Quim Fis, E-41012 Seville, Spain
关键词
ibrutinib; Leukemia; Density functional theory; Gold nanoparticle; Electron localization function; Density of states; INITIO MOLECULAR-DYNAMICS; TOTAL-ENERGY CALCULATIONS; ELECTRON LOCALIZATION; INHIBITORS;
D O I
10.1016/j.molliq.2020.113878
中图分类号
O64 [物理化学(理论化学)、化学物理学];
学科分类号
070304 ; 081704 ;
摘要
A theoretical study of the interaction of ibrutinib with both cysteine!methyl-cysteine and gold surface is presented. The interest of ibrutinib is that binds through its acrylamide group with the S atom from Cys481 residue of Bruton-tyrosine-ldnase (BTK) protein and inhibits the maturation of B-lymphocytes. In a first part, the interaction of ibrutinib through its acrylamide group with cysteine/methyl-cysteine is studied in the range of 298 to 315 K to analyse the effect of increasing the temperature in the binding of the drug with the amine-acid. The interaction is favoured at physiologic temperature but its stability decreases at higher temperatures. Thus, in patients with fever the drug may present a lower effectivity and certain amount of free drug in the blood may appear increasing the risk of toxicity for them. In the second part, the interaction of ibrutinib with a gold surface was studied to explore the possibility of using gold nanoparticles as ibrutinib deliverer. The most stable interaction corresponds to the structure with the nitrogen atoms from pyrimidine moiety and from NH2 directly focused over gold atoms keeping acrylamide group of ibrutinib free for joining to BTK. Therefore, according to the theoretical results gold nanoparticles may be used as ibrutinib deliverer. (C) 2020 Elsevier B.V. All rights reserved.
引用
收藏
页数:7
相关论文
共 46 条
  • [41] Outcomes in High-Risk Subgroups After Fixed-Duration Ibrutinib (Ibr) plus Venetoclax (Ven) for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Up to 5.5 Years of Follow-Up in the Phase 2 CAPTIVATE Study
    Wierda, William G.
    Jacobs, Ryan
    Barr, Paul M.
    Allan, John N.
    Siddiqi, Tanya
    Tedeschi, Alessandra
    Kipps, Thomas J.
    O'Brien, Susan M.
    Badoux, Xavier C.
    Visentin, Andrea
    Lasica, Masa
    Carney, Dennis
    Camburn, Anna Elinder
    De la Serna, Javier
    Szafer-Glusman, Edith
    Zhou, Cathy
    Szoke, Anita
    Dean, James P.
    Ghia, Paolo
    Tam, Constantine S.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S342 - S342
  • [42] The CLL12 trial protocol: a placebo-controlled double-blind Phase III study of ibrutinib in the treatment of early-stage chronic lymphocytic leukemia patients with risk of early disease progression
    Langerbeins, Petra
    Bahlo, Jasmin
    Rhein, Christina
    Cramer, Paula
    Pflug, Natali
    Fischer, Kirsten
    Stilgenbauer, Stephan
    Kreuzer, Karl Anton
    Wendtner, Clemens-Martin
    Eichhorst, Barbara
    Hallek, Michael
    FUTURE ONCOLOGY, 2015, 11 (13) : 1895 - 1903
  • [43] FFirst-line therapy in chronic lymphocytic leukemia: a Swedish nation-wide real-world study on 1053 consecutive patients treated between 2007 and 2013
    Sylvan, Sandra Eketorp
    Asklid, Anna
    Johansson, Hemming
    Klintman, Jenny
    Bjellvi, Jenny
    Tolvgard, Staffan
    Kimby, Eva
    Norin, Stefan
    Andersson, Per-Ola
    Karlsson, Claes
    Karlsson, Karin
    Lauri, Birgitta
    Mattsson, Mattias
    Sandstedt, Anna Bergendahl
    Strandberg, Maria
    Osterborg, Anders
    Hansson, Lotta
    HAEMATOLOGICA, 2019, 104 (04) : 797 - 805
  • [44] Ibrutinib versus bendamustine plus rituximab for first-line treatment of 65 or older patients with untreated chronic lymphocytic leukemia without del(17p)/TP53 mutation in China: a lifetime economic research study
    Yuan Hong
    Xichuang Chen
    Yuanquan Hong
    Xingfang Xiao
    Yan Wang
    Xiaohong You
    Jingyi Mi
    Tao Zhou
    Panpan Zheng
    Zhihu Huang
    BMC Health Services Research, 23
  • [45] Ibrutinib versus bendamustine plus rituximab for first-line treatment of 65 or older patients with untreated chronic lymphocytic leukemia without del(17p)/TP53 mutation in China: a lifetime economic research study
    Hong, Yuan
    Chen, Xichuang
    Hong, Yuanquan
    Xiao, Xingfang
    Wang, Yan
    You, Xiaohong
    Mi, Jingyi
    Zhou, Tao
    Zheng, Panpan
    Huang, Zhihu
    BMC HEALTH SERVICES RESEARCH, 2023, 23 (01)
  • [46] 6-Year Time to Next Treatment (TTNT) Extrapolation Curve for GLOW Study: First-Line Ibrutinib Plus Venetoclax (I plus V) Offers Long Treatment-Free Period for Older Adult/Unfit Patients With Chronic Lymphocytic Leukemia (CLL)
    Ossorio Prendes, Santiago
    Gimeno, Vicente
    Hernandez Rivas, Jose Angel
    Lopez Jimenez, Francisco Javier
    Diels, Joris
    Schioppa, Claudio
    Alfayate Lobo, Ana
    Dominguez-Lubillo, Teresa
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S355 - S356